Composition including stem cell-derived microvesicles for promoting neurogenesis

Abstract

The present invention relates to a composition including stem cell-derived microvesicles as an active ingredient for promoting neurogenesis. The stem cell-derived microvesicles according to the present invention can promote neurogenesis and migration of nerves and also promote angiogenesis in vascular endothelial cells, and thus can be usefully used in treatment of neurological damage.

1 . A composition for promoting neurogenesis, comprising stem cell-derived microvesicles as an active ingredient. 
     
     
         2 . The composition for promoting neurogenesis of  claim 1 , wherein the stem cell-derived microvesicles are microvesicles derived from stem cells induced by ischemic stimuli. 
     
     
         3 . The composition for promoting neurogenesis of  claim 2 , wherein the ischemic stimuli are to treat stem cells with ischemic brain extract. 
     
     
         4 . The composition for promoting neurogenesis of  claim 1 , wherein the stem cell-derived microvesicles are CD105-positive and annexin V-negative microvesicles. 
     
     
         5 . The composition for promoting neurogenesis of  claim 1 , wherein the stem cells comprise at least one selected from the group consisting of induced pluripotent stem cells (iPS), adult stem cells, embryonic stem cells, mesenchymal stem cells, adipose stem cells, hematopoietic stem cells, and cord blood stem cells. 
     
     
         6 . The composition for promoting neurogenesis of  claim 1 , wherein the cell-derived microvesicles promote neurogenesis and migration of neuronal cells. 
     
     
         7 . The composition for promoting neurogenesis of  claim 1 , wherein the cell-derived microvesicles promote angiogenesis of vascular endothelial cells. 
     
     
         8 . A method for promoting neurogenesis, comprising the step of applying stem cell-derived microvesicles to neural stem cells. 
     
     
         9 . The method for promoting neurogenesis of  claim 8 , wherein the stem cell-derived microvesicles are obtained by applying ischemic stimuli to stem cells. 
     
     
         10 . The method for promoting neurogenesis of  claim 9 , wherein the ischemic stimuli are to treat stem cells with ischemic brain extract. 
     
     
         11 . The method for promoting neurogenesis of  claim 8 , wherein the stem cells comprise at least one selected from the group consisting of induced. pluripotent stem cells (iPS), adult stem cells, embryonic stem cells, mesenchymal stem cells, adipose stem cells, hematopoietic stem cells, and cord blood stem cells. 
     
     
         12 . A pharmaceutical composition for prevention or treatment of degenerative neurological diseases, comprising stem cell-derived microvesicles as an active ingredient. 
     
     
         13 . The pharmaceutical composition for prevention or treatment of degenerative neurological diseases of  claim 12 , wherein the degenerative neurological disease comprises at least one selected from the group consisting of ischemic stroke, cerebral infarction, neurotrauma, Parkinson's disease, Lou Gehrig' disease, and epilepsy. 
     
     
         14 . A method for treating neurological damage, comprising the step of treating a subject other than human, suffering from neurological damage, with stem cell-derived microvesicles. 
     
     
         15 . The method for treating neurological damage of  claim 14 , wherein the neurological damage is neurological damage caused by a physical damage or degenerative neurological disease. 
     
     
         16 . The method for treating neurological damage of  claim 15 , wherein the physical damage comprises at least one selected from the group: consisting of brain trauma, spinal cord injury, and neurotrauma. 
     
     
         17 . The method for treating neurological damage of  claim 15 , wherein the degenerative neurological disease comprises at least one selected from the group consisting of ischemic stroke, cerebral infarction, neurotrauma, Parkinson's disease, Lou Gehrig' disease, and epilepsy. 
     
     
         18 . The method for treating neurological damage of  claim 14 , wherein the subject other than human comprises at least one selected from the group consisting of a rat, a red fox, a skunk, a raccoon, a badger, a dog, a wolf, a mongoose, a coyote, a weasel, and a cat. 
     
     
         19 . The method for treating neurological damage of  claim 14 , wherein the cell-derived microvesicles promote neurogenesis and migration of neuronal cells.